Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares [Yahoo! Finance]
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Yahoo! Finance
Zenas BioPharma secured a $250 million non-dilutive loan agreement to support commercialization and development of obexelimab. The financing follows positive Phase 3 clinical results and precedes planned marketing applications in the U.S. and Europe. Upcoming Phase 2 data for additional indications are expected to guide further development of the company's pipeline. Zenas BioPharma, listed as NasdaqGS:ZBIO, is drawing attention with this large non-dilutive funding package alongside a current share price of $23.23. The stock is up 175.6% over the past year, after declines of 11.1% over the past week, 12.0% over the past month, and 32.7% year to date. For investors tracking early commercial stage biotech names, this mix of strong one-year performance and recent pullback may warrant closer analysis. The new financing, tied to positive Phase 3 results for obexelimab and planned marketing submissions in the U.S. and Europe, provides additional capital for Zenas BioPharma's clinica
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma (ZBIO) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" MarketBeat
- Zenas BioPharma (ZBIO) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Zenas BioPharma (ZBIO) had its price target lowered by Citigroup Inc. from $43.00 to $41.00. They now have a "buy" rating on the stock.MarketBeat
- Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.MarketBeat
ZBIO
Earnings
- 3/16/26 - Miss
ZBIO
Sec Filings
- 3/16/26 - Form DEFA14A
- 3/16/26 - Form ARS
- 3/16/26 - Form DEF
- ZBIO's page on the SEC website